Method

Targeted radionuclide therapeutics

Radiopharmaceutical agents that conjugate cytotoxic radionuclides to targeting ligands or antibodies, delivering localized ionizing radiation to antigen-expressing cells via systemic administration.

AI-generated definition

Scholars using this

View all 5 scholars →

ST
Scott T. TagawaGebroe Family Professor of Hematology-Oncology in honor of Morton Coleman, M.D.
ST
Scott T. TagawaGebroe Family Professor of Hematology-Oncology in honor of Morton Coleman, M.D.
MM
Mark M SouweidaneMichels Family Professor of Pediatric Neurological Surgery
MM
Mark M SouweidaneMichels Family Professor of Pediatric Neurological Surgery
JR
Joseph Reginald OsborneProfessor of Radiology
JR
Joseph Reginald OsborneProfessor of Radiology
TJ
Thomas J FaheyJohnson and Johnson Distinguished Professor of Surgery
TJ
Thomas J FaheyJohnson and Johnson Distinguished Professor of Surgery
JK
James KellyAssistant Professor of Radiopharmaceutical Sciences in Radiology
JK
James KellyAssistant Professor of Radiopharmaceutical Sciences in Radiology

Spotlight

Targeted radionuclide therapeutics

STScott T. Tagawa HBHimisha Beltran MJMichael J. Morris

Lancet (London, England) · 2026

Targeted radionuclide therapeutics

STScott T. Tagawa VMValentina Marulanda Corzo SVShankar Vallabhajosula SHSandra Huicochea Castellanos+7 more →JRJoseph Reginald Osborne

Clinical cancer research : an official journal of the American Association for Cancer Research · 2026

Targeted radionuclide therapeutics

JRJoseph Reginald Osborne

European journal of nuclear medicine and molecular imaging · 2025

View all 13 publications →

Targeted radionuclide therapeutics

Scholars using this

Spotlight

Publications

Publications

Targeted radionuclide therapeutics

Scholars using this

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti-PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer.

Organ and tumour dosimetry of 177Lu-rhPSMA-10.1, a novel PSMA-targeted therapy: results from a Phase I trial.